Cevostamab

DB18374InvestigationalProtein Based Therapies

Cevostamab: Overview.

Mechanism: Pharmacologically active on T-cell surface glycoprotein CD3
Curator reviewed
Also known as: Anti-fcrh5/cd3 bite antibody bfcr4350a · Bfcr4350a (anti-fcrh5/cd3 t-cell dependent bispecific antibody) · Fcrh5/cd3 t cell dependent bispecific antibody bfcr4350a · Recombinant anti-fcrh5 x anti-cd3 bi-specific t-cell engager bfcr4350a
Code names: BFCR-4350A · RO-7187797

Resolves to

Compound

What you can answer from here — as of July 11, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of Cevostamab, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.